Evidence map›Paper›PMID 32107180›Full record

ArticleJournal of clinical lipidology

Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies.

Ambika P Ashraf, Kazuya Miyashita, Katsuyuki Nakajima, Masami Murakami, Robert A Hegele, Michael Ploug, Loren G Fong, Stephen G Young, Anne P Beigneux

Open access · greenAbstract readCase Reports
In one paragraph

Article in Journal of clinical lipidology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. A protein of capillary endothelial cells, GPIHBP1, is crucial for plasma triglyceride metabolism.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  8. Case Studies in Pediatric Lipid Disorders and Their Management.The Journal of clinical endocrinology and metabolism · 2021
    Article
  9. Review
  10. Chylomicronemia from GPIHBP1 autoantibodies.Journal of lipid research · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 4 countries.

Ambika P AshrafDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: AAshraf@peds.uab.edu.
Kazuya MiyashitaImmuno-Biological Laboratories (IBL), Fujioka, Gunma, Japan.
Katsuyuki NakajimaDepartment of Clinical Laboratory Medicine, Gunma University, Graduate School of Medicine, Maebashi, Japan.
Masami MurakamiDepartment of Clinical Laboratory Medicine, Gunma University, Graduate School of Medicine, Maebashi, Japan.
Robert A HegeleRobarts Research Institute, Western University, London, Ontario, Canada.
Michael PlougFinsen Laboratory, Rigshospitalet, Copenhagen N, Denmark; Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Copenhagen N, Denmark.
Loren G FongDepartments of Medicine and Human Genetics, David Geffen School of Medicine, University of California Los Angeles, CA, USA.
Stephen G YoungDepartments of Medicine and Human Genetics, David Geffen School of Medicine, University of California Los Angeles, CA, USA; Departments of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. Electronic address: sgyoung@mednet.ucla.edu.
Anne P BeigneuxDepartments of Medicine and Human Genetics, David Geffen School of Medicine, University of California Los Angeles, CA, USA. Electronic address: abeigneux@mednet.ucla.edu.
University of California, Los Angeles · USGunma University · JPMedical & Biological Laboratories (Japan) · JPUniversity of Alabama at Birmingham Hospital · USUniversity of Copenhagen · DKWestern University · CA

Funding

The Lipin Protein Family and Triglyceride Metabolism P01HL090553 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YOUNG, STEPHEN G. · 2008 to 2018
$23.3M
University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ANANDA BASU · 2013 to 2026
$19.5M
Understanding the Influence of Lipid Homeostasis on T cell FunctionP01HL146358 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FONG, LOREN GI · 2019 to 2023
$11.7M
Refining Physiologic Mechanisms for Intravascular Triglyceride MetabolismR01HL087228 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BEIGNEUX, ANNE, FONG, LOREN GI · 2007 to 2024
$7.8M
Investigating Mechanisms for Lipid Transport in Health and DiseaseR35HL139725 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YOUNG, STEPHEN G. · 2018 to 2024
$6.1M
Defining mechanisms for lipid transport across capillary endothelial cellsR01HL125335 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YOUNG, STEPHEN G. · 2015 to 2017
$1.2M
NHLBI NIH HHS P01 HL090553NHLBI NIH HHS P01 HL146358NHLBI NIH HHS R01 HL087228NHLBI NIH HHS R01 HL125335NHLBI NIH HHS R35 HL139725NIDDK NIH HHS P30 DK079626
6 · The paper itself

Abstract

Chylomicronemia caused by a deficiency in lipoprotein lipase (LPL) or GPIHBP1 (the endothelial cell protein that transports LPL to the capillary lumen) is typically diagnosed during childhood and represents a serious, lifelong medical problem. Affected patients have high plasma triglyceride levels (>1500 mg/dL) and a high risk of acute pancreatitis. However, chylomicronemia frequently presents later in life in the absence of an obvious monogenic cause. In these cases, the etiology for the chylomicronemia is presumed to be "multifactorial" (involving diabetes, drugs, alcohol, or polygenic factors), but on a practical level, the underlying cause generally remains a mystery. Here, we describe a 15-year-old female with chylomicronemia caused by GPIHBP1 autoantibodies (which abolish LPL transport to the capillary lumen). Remarkably, chylomicronemia in this patient was intermittent, interspersed between periods when the plasma triglyceride levels were normal. GPIHBP1 autoantibodies were easily detectable during episodes of chylomicronemia but were undetectable during periods of normotriglyceridemia. During the episodes of chylomicronemia (when GPIHBP1 autoantibodies were present), plasma LPL levels were low, consistent with impaired LPL transport into capillaries. During periods of normotriglyceridemia, when GPIHBP1 autoantibodies were absent, plasma LPL levels normalized. Because the chylomicronemia in this patient was accompanied by debilitating episodes of acute pancreatitis, the patient was ultimately treated with immunosuppressive drugs, which resulted in disappearance of GPIHBP1 autoantibodies and normalization of plasma triglyceride levels. GPIHBP1 autoantibodies need to be considered in patients who present with unexplained acquired cases of chylomicronemia.

Indexed as

AdolescentAutoantibodiesFemaleHumansHyperlipoproteinemia Type IReceptors, LipoproteinAutoantibodiesGPIHBP1 protein, humanReceptors, LipoproteinGPIHBP1lipoprotein lipaseLPL

Identifiers

PMID32107180
PMCPMC7166156
OpenAlexW3003487350

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.